Madrigal Pharmaceuticals | Company Profile
Company Directory for Madrigal Pharmaceuticals
Madrigal Pharmaceuticals
Overview
Madrigal Pharmaceuticals is a biopharmaceutical company based in Pennsylvania, founded in 2016 by CMO Rebecca Taub. The company specializes in developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can lead to severe complications such as cirrhosis and liver cancer.
Madrigal has achieved the first U.S. FDA-approved treatment for MASH, focusing on halting or reversing liver fibrosis. The company conducts extensive research and clinical trials to advance therapies targeting the pathology of MASH. Its R&D strategy includes both early safety studies and large-scale Phase 3 clinical trials, emphasizing the development of therapeutics that aim to improve clinical outcomes for patients suffering from this condition.
Basic Information
| Industry | pharmaceuticals |
|---|---|
| Founded | 2016 |
| Revenue | 180.1M |
| Headquarters | 200 Barr Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, United States |
| Alexa Ranking |
Contact Details
- Phone: +1 610-937-1951
- Website: madrigalpharma.com
- LinkedIn: linkedin.com/company/madrigal-pharmaceuticals-inc-
Key Focus Areas & Initiatives
- Liver disease research
- Development of novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH)
- FDA-approved treatment for MASH
- Halting or reversing liver fibrosis progression
- Phase 3 clinical trials and research programs
- Therapeutic approaches for cirrhosis and liver cancer
- Improving clinical outcomes for patients
Technologies Used
- Cloudflare DNS
- Drupal
- Microsoft Office 365
- Mimecast